Prostate International

Papers
(The TQCC of Prostate International is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Prostate diseases and microbiome in the prostate, gut, and urine36
Management and treatment options for patients with de novo and recurrent hormone-sensitive oligometastatic prostate cancer31
Performance of Ga-68 PSMA PET/CT for diagnosis and grading of local prostate cancer20
Efficacy and safety of apalutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a subgroup analysis of a randomized, double-blind, placebo-controlled, Phase-3 study18
Radiation-induced haemorrhagic cystitis after prostate cancer radiotherapy: factors associated to hospitalization and treatment strategies17
Changes in diagnosis rate and treatment trends of benign prostatic hyperplasia in Korea: A nationwide population-based cohort study14
Open simple prostatectomy and robotic simple prostatectomy for large benign prostatic hyperplasia: Comparison of safety and efficacy13
Update on the management of benign prostatic hyperplasia and the role of minimally invasive procedures12
A systematic review of outcomes after thermal and nonthermal partial prostate ablation12
Impact of positive surgical margin on biochemical recurrence in localized prostate cancer12
Comparing open and robotic salvage radical prostatectomy after radiotherapy: predictors and outcomes11
Changing trends in robot-assisted radical prostatectomy: Inverse stage migration—A retrospective analysis11
Robotic-assisted simple prostatectomy versus holmium laser enucleation of the prostate for large benign prostatic hyperplasia: A single-center preliminary study in Korea10
Micro-Ultrasound: a way to bring imaging for prostate cancer back to urology10
Association of serum prostate-specific antigen (PSA) level and circulating tumor cell-based PSA mRNA in prostate cancer10
Rebiopsy rate after transperineal or transrectal prostate biopsy10
Impact of the evolving United States Preventative Services Task Force policy statements on incidence and distribution of prostate cancer over 15 years in a statewide cancer registry10
Robotic-assisted radical prostatectomy: learning curves and outcomes from an Australian perspective9
Risk factors associated with pain in fusion prostate biopsy9
Biparametric versus multiparametric magnetic resonance imaging of the prostate: detection of clinically significant cancer in a perfect match group9
Comparison of a combined regimen of fosfomycin and ciprofloxacin with ciprofloxacin alone as antimicrobial prophylaxis for transrectal prostate biopsy in the era of high fluoroquinolone-resistant rect8
Androgen deprivation therapy and risk of cognitive dysfunction in men with prostate cancer: is there a possible link?8
Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer8
Revision of CHAARTED and LATITUDE criteria among Japanese de novo metastatic prostate cancer patients8
Diagnostic performance of MRI for prediction of recurrent prostate cancer after high-intensity focused ultrasound: a systematic review and meta-analysis8
Diagnostic yield of multiparametric MRI for local recurrence at biochemical recurrence after radical prostatectomy8
RNA-seq profile of African American men with a clinically localized prostate cancer8
Genomic analysis and long-term outcomes of a phase 1 clinical trial on cytoreductive radical prostatectomy8
Initial experience of single-port robot-assisted radical prostatectomy: A single surgeon's experience with technique description8
Topical antiseptic at time of transrectal ultrasound prostate biopsy is associated with fewer severe clinical infections and improves antibiotic stewardship8
DNA methylation biomarkers distinguishing early-stage prostate cancer from benign prostatic hyperplasia7
Temporal changes of PIRADS scoring by radiologists and correlation to radical prostatectomy pathological outcomes7
Minimal invasive management of bladder neck contracture using Allium round posterior stent: the long-term results7
The value of magnetic resonance imaging and ultrasonography (MRI/US)-fusion biopsy in clinically significant prostate cancer detection in patients with biopsy-naïve men according to PSA levels: A prop7
The significance of the visible tumor on preoperative magnetic resonance imaging in localized prostate cancer7
Prostate-specific antigen kinetics contributes to decision making for biopsy referral: the predictive implication for PSA retest in patients with elevated PSA levels6
Factors affecting biochemical recurrence of prostate cancer after radical prostatectomy in patients with positive and negative surgical margin6
Multiparametric magnetic resonance imaging and clinical variables: Which is the best combination to predict reclassification in active surveillance patients?6
Effectiveness of magnetic resonance imaging–targeted biopsy for detection of prostate cancer in comparison with systematic biopsy in our countries with low prevalence of prostate cancer: our first exp6
Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer6
Artificial intelligence in urologic oncology: the actual clinical practice results of IBM Watson for Oncology in South Korea6
Enhanced inhibition of tumor growth using TRAIL-overexpressing adipose-derived stem cells in combination with the chemotherapeutic agent CPT-11 in castration-resistant prostate cancer6
Possibilities and limitations of using low biomass samples for urologic disease and microbiome research6
Comparative efficacy and safety profile of 4 vs 8 mg of silodosin once daily usage in patients with benign prostatic hyperplasia–related lower urinary tract symptoms divided into subgroups according t6
Androgen deprivation therapy may reduce the risk of primary open-angle glaucoma in patients with prostate cancer: a nationwide population-based cohort study6
Expression of hsv1-miR-H18 and hsv2-miR-H9 as a field defect marker for detecting prostate cancer6
0.029446125030518